Skip to main content
Terug
Watch Compare

Enveric Biosciences, Inc.

Datakwaliteit: 83%
ENVB
NASDAQ Manufacturing Chemicals
€ 1,96
▼ € 0,07 (-3,30%)
Marktkapitalisatie: 3,83 M
Prijs
€ 2,03
Marktkapitalisatie
3,83 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Negative free cash flow of -8,14 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-311,01%
Onder sectorgemiddelde (-54,01%)
ROIC-245,77%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio4,60
Interest Coverage-82777,81

Waardering

PE (TTM)
-0,44
Boven sectorgemiddelde (-1,49)
P/B Ratio1,11
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1385 peers)
Metriek Aandeel Sector Mediaan
P/E -0,4 -1,5
P/B 1,1 1,6
ROE % -311,0 -54,0
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Geen toekomstige schattingen beschikbaar

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42024 -€ 2,76 -€ 2,03 +26,4%
Q32024 N/A -€ 43,20 —
Q22024 -€ 99,00 -€ 45,00 +54,6%
Q12024 -€ 139,50 -€ 109,80 +21,3%

ETFs Holding This Stock

PSIL logo PSIL AdvisorShares Psychedelics ETF
0,76% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -8,77 M
ROE -311,01% ROA -221,78%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -8,14 M
ROIC -245,77% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 4,60
Interest Coverage -82777,81 Asset Turnover N/A
Working Capital 3,26 M Tangible Book Value 3,41 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,44 Forward P/E N/A
P/B Ratio 1,11 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -212,49%
Market Cap 3,83 M Enterprise Value 3,83 M
Per Share
EPS (Diluted TTM) -36,24 Revenue / Share N/A
FCF / Share -4,31 OCF / Share -4,31
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 92,81%
SBC-Adj. FCF -9,10 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -8,77 M -9,57 M -17,29 M -18,47 M -48,98 M
EPS (Diluted) -36,24 -19,04 -8,09 — —
Gross Profit — — — — —
Operating Income -8,77 M -9,63 M -16,45 M -27,42 M -64,62 M
EBITDA — — — — —
R&D Expenses 2,78 M 2,84 M 7,25 M 8,03 M 4,79 M
SG&A Expenses — — — — 20,50 M
D&A 200.858,0 337.489,0 343.982,0 327.910,0 656.643,0
Interest Expense -106,0 219,0 3.708,0 5.249,0 10.316,0
Income Tax 8.930,0 8.930,0 28.913,0 -1,49 M -7,45 M

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2021 FY2022
Total Assets 5,10 M 3,08 M 4,30 M 26,72 M 19,55 M
Total Liabilities — — — 4,41 M 4,00 M
Shareholders' Equity 4,18 M 1,59 M 1,96 M 22,31 M 14,67 M
Total Debt — — — — —
Cash & Equivalents — — — — —
Current Assets 4,94 M 2,73 M 3,58 M 17,74 M 18,43 M
Current Liabilities 918.400,0 1,49 M 2,34 M 2,08 M 4,00 M